AR020048A1 - Un polipeptido dependiente de la vitamina k, una composicion farmaceutica que lo comprende, el uso del mismo para la manufactura de un medicamento, unacido nucleico aislado que codifica a dicho polipeptido y una celula hospedante de mamifero. - Google Patents

Un polipeptido dependiente de la vitamina k, una composicion farmaceutica que lo comprende, el uso del mismo para la manufactura de un medicamento, unacido nucleico aislado que codifica a dicho polipeptido y una celula hospedante de mamifero.

Info

Publication number
AR020048A1
AR020048A1 ARP980105278A ARP980105278A AR020048A1 AR 020048 A1 AR020048 A1 AR 020048A1 AR P980105278 A ARP980105278 A AR P980105278A AR P980105278 A ARP980105278 A AR P980105278A AR 020048 A1 AR020048 A1 AR 020048A1
Authority
AR
Argentina
Prior art keywords
polypeptide
vitamin
manufacture
pharmaceutical composition
isolated nucleic
Prior art date
Application number
ARP980105278A
Other languages
English (en)
Original Assignee
Univ Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minnesota filed Critical Univ Minnesota
Publication of AR020048A1 publication Critical patent/AR020048A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Un polipéptido dependiente de la vitamina K, que comprende un dominio GLA modificado que acentua o refuerza la afinidad para vincularse a las membranas, dedicho polipéptido con respecto a un correspondiente polipéptido nativo dependiente de la vitamina k, comprendiendo dicho dominio GLA modificado, por lo menosuna sustitucion de amino ácido; una composicion farmacéutica que lo comprende, el uso del mismo para la manufactura de un medicamento, un ácido nucleicoaislado que codifica a dicho polipéptido y una célula hospedante de mamífero.
ARP980105278A 1997-10-23 1998-10-22 Un polipeptido dependiente de la vitamina k, una composicion farmaceutica que lo comprende, el uso del mismo para la manufactura de un medicamento, unacido nucleico aislado que codifica a dicho polipeptido y una celula hospedante de mamifero. AR020048A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/955,636 US6017882A (en) 1997-10-23 1997-10-23 Modified vitamin K-dependent polypeptides

Publications (1)

Publication Number Publication Date
AR020048A1 true AR020048A1 (es) 2002-04-10

Family

ID=25497114

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP980105278A AR020048A1 (es) 1997-10-23 1998-10-22 Un polipeptido dependiente de la vitamina k, una composicion farmaceutica que lo comprende, el uso del mismo para la manufactura de un medicamento, unacido nucleico aislado que codifica a dicho polipeptido y una celula hospedante de mamifero.
ARP020101003A AR035786A2 (es) 1997-10-23 2002-03-20 Variantes de factores de coagulacion dependientes de vitamina k y composiciones que los contienen

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP020101003A AR035786A2 (es) 1997-10-23 2002-03-20 Variantes de factores de coagulacion dependientes de vitamina k y composiciones que los contienen

Country Status (30)

Country Link
US (1) US6017882A (es)
EP (2) EP1090128B1 (es)
JP (1) JP4276379B2 (es)
KR (1) KR20010031370A (es)
CN (1) CN1246462C (es)
AP (1) AP2000001811A0 (es)
AR (2) AR020048A1 (es)
AT (1) ATE390486T1 (es)
AU (1) AU749279C (es)
BR (1) BR9814611A (es)
CA (1) CA2307175C (es)
DE (1) DE69839313T2 (es)
DK (1) DK1090128T3 (es)
EA (1) EA200000449A1 (es)
ES (2) ES2303362T3 (es)
HR (1) HRP20000234A2 (es)
HU (1) HU225993B1 (es)
ID (1) ID26330A (es)
IL (1) IL135603A0 (es)
IS (1) IS5449A (es)
MY (1) MY136336A (es)
NO (1) NO20002025L (es)
NZ (1) NZ504114A (es)
PL (1) PL194194B1 (es)
PT (1) PT1090128E (es)
SG (1) SG105547A1 (es)
TR (1) TR200001105T2 (es)
TW (1) TW587081B (es)
WO (1) WO1999020767A1 (es)
ZA (1) ZA989597B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6747003B1 (en) * 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7247708B2 (en) * 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6693075B1 (en) * 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6998122B1 (en) 1999-04-30 2006-02-14 Eli Lilly And Company Protein C derivatives
CA2391651A1 (en) * 1999-11-19 2001-05-25 Eli Lilly And Company Protein c derivatives
AU2001232736A1 (en) 2000-02-02 2001-08-14 Eli Lilly And Company Protein c derivatives
WO2001058935A2 (en) 2000-02-11 2001-08-16 Maxygen Aps FACTOR VII OR VIIa-LIKE MOLECULES
WO2001059084A1 (en) 2000-02-11 2001-08-16 Eli Lilly And Company Protein c derivatives
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US6423826B1 (en) 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
US7160540B2 (en) * 2000-06-30 2007-01-09 Regents Of The University Of Minnesota Methods for detecting activity of clottings factors
AU2001278336B2 (en) * 2000-07-31 2007-01-18 Ottawa Heart Institute Research Corporation Charged phospholipid compositions and methods for their use
US6933367B2 (en) 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
AU2002235073B2 (en) * 2001-03-02 2007-02-01 T.A.C. Thrombosis And Coagulation Ab Protein C variants
WO2003073980A2 (en) * 2002-03-01 2003-09-12 T.A.C. Thrombosis And Coagulation Aktiebolag Recombinant protein c variants
US20030186862A1 (en) * 2002-04-02 2003-10-02 Nelsestuen Gary L. Factor VIIa compositions
DE60334983D1 (de) * 2002-04-30 2010-12-30 Bayer Healthcare Llc Faktor vii oder faktor viia polypeptidvarianten
US20030232075A1 (en) * 2002-05-06 2003-12-18 University Of Minnesota, A Minnesota Corporation Compositions for producing factor Xa
CN101912601B (zh) 2002-06-21 2012-08-29 诺和诺德医疗保健公司 因子vii多肽的稳定化固体组合物
US20040176704A1 (en) * 2003-03-04 2004-09-09 Stevens Timothy A Collection device adapted to accept cartridge for point of care system
EP3103869A1 (en) 2003-03-18 2016-12-14 Novo Nordisk Health Care AG Method for the production of factor vii polypeptides
EP2085470B1 (en) * 2003-03-20 2012-05-16 Bayer HealthCare LLC FVII or FVIIa variants
JP4915918B2 (ja) * 2003-06-19 2012-04-11 バイエル ヘルスケア エルエルシー 第ＶＩＩ因子または第ＶＩＩａ因子のＧｌａドメイン変種
CN101870729A (zh) 2003-09-09 2010-10-27 诺和诺德医疗保健公司 凝固因子ⅶ多肽
KR100755967B1 (ko) * 2003-10-23 2007-09-06 한국타이어 주식회사 타이어의 비드와 휠의 갭 측정장치
AU2004294403A1 (en) 2003-12-01 2005-06-16 Novo Nordisk Health Care Ag Nanofiltration of factor VII solutions to remove virus
EP2311437A1 (en) 2003-12-19 2011-04-20 Novo Nordisk Health Care AG Stabilised compositions of factor VII polypeptides
EP2033662B1 (en) 2004-01-21 2012-10-17 Novo Nordisk Health Care AG Transglutaminase mediated conjugation of peptides
EP1831242B1 (en) 2004-12-23 2012-09-26 Novo Nordisk Health Care AG Reduction of the content of protein contaminants in compositions comprising a vitamin k-dependent protein of interest
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
WO2006114105A2 (en) * 2005-04-26 2006-11-02 Maxygen Holdings Ltd. Use of modified factor vii for treating bleeding
US8633300B2 (en) 2005-06-17 2014-01-21 Novo Nordisk Healthcare Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
JP5147692B2 (ja) 2005-07-13 2013-02-20 ノボ ノルディスク ヘルス ケア アーゲー 治療用タンパク質生成のための宿主細胞タンパク質ノックアウト細胞
CN101268185B (zh) 2005-09-01 2013-03-27 诺沃-诺迪斯克保健股份有限公司 因子ⅶ多肽的疏水作用色谱纯化
JP5690047B2 (ja) 2005-09-14 2015-03-25 ノボ ノルディスク ヘルス ケア アーゲー ヒト凝固第ｖｉｉ因子ポリペプチド
US20100056428A1 (en) 2006-09-01 2010-03-04 Novo Nordisk Health Care Ag Modified proteins
WO2008078189A2 (en) * 2006-12-20 2008-07-03 Bayer Healthcare Llc Factor vii and viia compositions
RU2571931C2 (ru) 2007-04-13 2015-12-27 Каталист Биосайенсис, Инк. Полипептиды на основе модифицированного фактора vii и их применение
US20080305157A1 (en) * 2007-06-08 2008-12-11 University Of Maryland Office Of Technology Commercialization Encapsulation and separation of charged organic solutes inside catanionic vesicles
SI2574677T1 (sl) 2007-12-27 2017-11-30 Baxalta GmbH Procesi celične kulture
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
DK3266463T3 (da) 2009-06-09 2024-01-08 Prolong Pharmaceuticals Llc Hæmoglobinsammensætninger
CN102686603B (zh) * 2009-12-14 2014-12-17 国立大学法人北海道大学 对脂质膜结构体赋予细胞透过能力和/或增强脂质膜结构体的细胞透过能力的肽、以及含有与这些肽结合了的脂质作为构成脂质的具有细胞透过能力或细胞透过能力得到增强的脂质膜结构体
TWI595004B (zh) 2010-11-03 2017-08-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
KR102049900B1 (ko) 2012-07-25 2019-11-28 카탈리스트 바이오사이언시즈, 인코포레이티드 변형 인자 x 폴리펩티드 및 이의 용도
US11491212B1 (en) 2017-09-27 2022-11-08 Catalyst Biosciences, Inc. Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
EP3833381B1 (en) 2019-08-15 2022-08-03 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration
WO2021154414A2 (en) 2020-01-29 2021-08-05 Catalyst Biosciences, Inc. Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0296413A2 (en) * 1987-06-12 1988-12-28 Hoechst Japan Limited Hybrid protein C and method for its preparation
JPH0246296A (ja) * 1988-08-09 1990-02-15 Hoechst Japan Ltd 雑種プロテインｃ及びその製造方法
US5580560A (en) * 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
ATE180834T1 (de) * 1990-01-29 1999-06-15 Zymogenetics Inc Antikoagulierende proteine
US5504064A (en) * 1991-04-10 1996-04-02 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with an activator of FVII

Also Published As

Publication number Publication date
IL135603A0 (en) 2001-05-20
ES2303362T3 (es) 2008-08-01
TR200001105T2 (tr) 2000-09-21
EP1090128B1 (en) 2008-03-26
PT1090128E (pt) 2008-04-17
AP2000001811A0 (en) 2000-06-30
NZ504114A (en) 2002-10-25
HUP0102257A2 (hu) 2001-09-28
JP4276379B2 (ja) 2009-06-10
AU749279B2 (en) 2002-06-20
ES2496104T3 (es) 2014-09-18
EP1676919A1 (en) 2006-07-05
ATE390486T1 (de) 2008-04-15
EA200000449A1 (ru) 2000-12-25
CA2307175C (en) 2009-04-14
NO20002025D0 (no) 2000-04-18
WO1999020767A1 (en) 1999-04-29
HU225993B1 (en) 2008-02-28
DK1090128T3 (da) 2008-06-23
BR9814611A (pt) 2000-10-03
CN1283231A (zh) 2001-02-07
HRP20000234A2 (en) 2001-08-31
MY136336A (en) 2008-09-30
ZA989597B (en) 1999-04-23
NO20002025L (no) 2000-06-19
EP1090128A1 (en) 2001-04-11
AR035786A2 (es) 2004-07-14
IS5449A (is) 2000-04-14
DE69839313D1 (de) 2008-05-08
JP2001520042A (ja) 2001-10-30
ID26330A (id) 2000-12-14
HUP0102257A3 (en) 2003-09-29
CA2307175A1 (en) 1999-04-29
US6017882A (en) 2000-01-25
AU2702499A (en) 1999-05-10
DE69839313T2 (de) 2009-04-16
AU749279C (en) 2004-09-16
KR20010031370A (ko) 2001-04-16
CN1246462C (zh) 2006-03-22
EP1676919B1 (en) 2014-07-23
PL340284A1 (en) 2001-01-29
SG105547A1 (en) 2004-08-27
PL194194B1 (pl) 2007-05-31
TW587081B (en) 2004-05-11

Similar Documents

Publication Publication Date Title
Lupetti et al. Candidacidal activities of human lactoferrin peptides derived from the N terminus
Yang et al. In vivo residue‐specific dopa‐incorporated engineered mussel bioglue with enhanced adhesion and water resistance
BR9406232A (pt) Novo agente para controle da atividade celular
Groebe et al. Determinants involved in the affinity of α-conotoxins GI and SI for the muscle subtype of nicotinic acetylcholine receptors
ATE408699T1 (de) Verabreichung von nukleinsäuren und proteinen an zellen
BR9713294A (pt) "anticorpos contra proteìna relacionada a hormÈnio de paratiróide humano"
HUP0102257A2 (hu) Módosított K-vitamin-dependens polipeptidek
EP0695171A1 (en) GONADOTROPINE CONTAINING FREEZER DRIED DROPS
BRPI9610511B8 (pt) construções de dna, úteis em terapia genética, compreendendo ao menos uma sequência nucléica de interesse e composição farmacêutica.
AR004668A1 (es) Un acido nucleico aislado purificado, un vector de expresion recombinante que lo comprende, una celula que comprende dicho vector, un metodo para laproduccion de un polipeptido de h.pylori, una composicion de vacuna, el uso de dicha composicion para preparar medicamentos, un polipeptido purificado de h.
AR038568A1 (es) Anticuerpos anti-a beta y su uso
BRPI0113286B8 (pt) pirazóis substituídos e composição farmacêutica compreendendo os mesmos.
ES2056817T5 (es) Transformacion de trichoderma.
BR0316435A (pt) Produtos genéticos expressos diferencialmente em tumores e uso dos mesmos
BR9814404A (pt) " clonagem de expressão em fungos filamentosos "
EP4063385A4 (en) GIPR ANTIBODIES AND FUSION PROTEIN BETWEEN THE SAME AND GLP-1 AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
WO2002002783A3 (en) Expression vectors
Ryu et al. Protein‐stabilizing and cell‐penetrating properties of α‐helix domain of 30Kc19 protein
BR0014465A (pt) 1,1'-bifenil-2-carbonamidas 2'-substituìdas, processos para a sua preparação,seu emprego como medicamento bem como os preparados farmacêuticos contendo as mesmas
NO20052363L (no) Interferon-alfa polypeptider og konjugater
BR0312521A (pt) Métodos para a separação e a purificação de fibrinogênio e de pelo menos uma outra proteìna e para a co-purificação de fibrinogênio e de fator xiii, uso de cromatografia de afinidade com ìon de metal imobilizado, fibrinogênio, kit farmacêutico, e, formulações farmacêutica e de fibrinogênio liofilizado
BR9509172A (pt) Proteina de via de complemento nativa sequéncia de dna construção de dna conjugado uso de uma proteína processo para reduzir proteina de via de complemento em um mamifero e formulação farmacéutica
ES2173471T3 (es) Analisis para homocisteina y homocisteina desulfurasa a partir de tricomonas viginalis de protozoos.
WO2001012661A3 (en) RECEPTOR-MEDIATED UPTAKE OF AN EXTRACELLULAR BCL-xL FUSION PROTEIN INHIBITS APOPTOSIS
AR023699A1 (es) Una composicion farmaceutica que comprende un estabilizador de insulina y un procedimiento para preparar una composicion farmaceutica